rethinkPeptides Search
Menu
Study breakdown

How Vitamin C Can Be Paired with Drugs, Peptides, and Proteins to Improve Targeted Therapy

evidence
The takeaway

Linking vitamin C to drugs, peptides, and proteins creates a 'Trojan horse' delivery system that helps therapies reach their targets more effectively, including crossing the blood-brain barrier.

Trojan Horse Platform

Vitamin C conjugation exploits cells' natural nutrient uptake to deliver drugs, peptides, and proteins past biological barriers including the blood-brain barrier

What the researchers found

Vitamin C conjugation serves as a versatile 'Trojan horse' platform for drug delivery. When drugs like diclofenac, aspirin, and naproxen are linked to vitamin C, they gain improved transport across the blood-brain barrier via SVCT-mediated uptake, opening potential treatments for neurodegenerative disorders. Antiviral conjugates such as saquinavir-vitamin C show enhanced oral absorption by bypassing efflux mechanisms.

Peptide-vitamin C conjugates leverage the antioxidant properties of vitamin C alongside peptide-based cellular targeting, providing synergistic benefits particularly in cosmetics and dermatology. Protein conjugates using carriers like human serum albumin (HSA) and bovine serum albumin (BSA) facilitate improved systemic transport, while nanostructure incorporation enhances oxidative stability and intracellular delivery through endocytosis.

Why it matters

Drug delivery remains one of the biggest challenges in medicine — many promising therapies fail because they can't reach their targets effectively. This review highlights how a simple, naturally occurring nutrient (vitamin C) can be used as a molecular 'ticket' to smuggle drugs past biological barriers. The peptide conjugation angle is especially relevant for developing next-generation cosmeceuticals and targeted dermatological treatments.

How the study worked

This is a comprehensive review article that synthesizes findings from multiple published studies on vitamin C conjugation strategies. The authors examined research across several conjugation categories: small-molecule drugs, polymers, lipids, peptides, natural compounds, proteins, and nanostructures such as gold nanoparticles.

What this study cannot tell us

As a review article, this study does not present new experimental data. The effectiveness of many described conjugates has only been demonstrated in laboratory settings, and clinical translation remains limited. The review may also be subject to selection bias in the studies it chose to highlight, and long-term safety data for most vitamin C conjugates is not discussed.

How to read the evidence

This is a narrative review article synthesizing existing literature on vitamin C conjugation. While it provides a broad overview of the field, it does not present original experimental data or use systematic review methodology, placing it in the lower tiers of the evidence hierarchy.

When this study was published

Published in 2026, this is a very recent review capturing the current state of vitamin C conjugation research including the latest advances in peptide and protein conjugate strategies.

The bigger picture

Vitamin C conjugation sits at the intersection of nutritional biochemistry and drug delivery science. As targeted therapies and precision medicine advance, the need for smarter delivery systems grows. This approach joins other nutrient-based delivery strategies (like folate and biotin conjugation) in exploiting the body's own nutrient uptake machinery, with peptide conjugates representing a particularly promising frontier for combining targeting specificity with antioxidant protection.

Questions still open

  • How do vitamin C-peptide conjugates compare to other nutrient-peptide conjugation strategies in terms of targeting efficiency?
  • What are the regulatory pathways for bringing vitamin C conjugate therapies from the lab to clinical use?
  • Could vitamin C conjugation improve delivery of emerging peptide therapeutics for neurodegenerative diseases?

Common questions

What is a vitamin C-drug conjugate and how does it work?
A vitamin C-drug conjugate is a molecule created by chemically linking a drug to vitamin C. Because cells actively absorb vitamin C to survive, they inadvertently take up the attached drug as well — a strategy scientists call a 'Trojan horse' approach. This can help drugs cross biological barriers like the blood-brain barrier and overcome drug resistance.
How are peptides used in vitamin C conjugation?
Peptides can be linked to vitamin C to create conjugates that combine the antioxidant properties of the vitamin with the targeting ability of peptides. These peptide-vitamin C conjugates are particularly promising in cosmetics and dermatology, where they can deliver antioxidant benefits to specific skin cells while the peptide component provides targeted biological activity.

Read the original research

Vitamin C Conjugates in Biomedicine: A Comprehensive Exploration with Drugs, Polymers, Proteins, and Peptides.

Mini reviews in medicinal chemistry

Citation

Wavhale, Sarika R; Shaikh, Anwar R. (2026). Vitamin C Conjugates in Biomedicine: A Comprehensive Exploration with Drugs, Polymers, Proteins, and Peptides.. Mini reviews in medicinal chemistry. https://doi.org/10.2174/0113895575257065251113073957